The Hydroxyphenyl Ester Series Veterinary Grade API is supplied as a white or off-white crystalline powder produced by esterification of the phenolic hydroxyl with a short-chain aliphatic or aromatic carboxylic acid. The esterification changes solid-state packing, aqueous solubility, hygroscopicity, and oxidative stability relative to the free phenolic active moiety. Model designations are manufacturer-specific and encode the ester chain length, residual free phenol limit, and dosage-form grade; typical grade designators include oral solid, injectable, and premix variants, but these must be read against the certificate of analysis because the active moiety remains the same while the ester substituent changes molecular weight. A representative specification includes an HPLC assay of 98.0% to 102.0% on the dried basis, water content by USP <921> Method Ia not more than 0.5% for non-sterile grades and 0.2% for injectable grades, residue on ignition not more than 0.1%, loss on drying at 105 °C for 2 h according to USP <731>, and related substances with free phenolic impurity controlled at ≤1.0% for oral grades and ≤0.5% for injectable grades. Residual solvents are controlled under ICH Q3C and VICH GL18; elemental impurities are controlled under ICH Q3D. The veterinary grade designation indicates manufacturing under API GMP aligned with ICH Q7; the material is not automatically certified as human-grade and may carry a wider impurity or residual solvent acceptance range in some jurisdictions. The series is used in tablets, capsules, powder sachets, granulated oral powders, feed premixes, and aqueous or co-solvent-based solutions. The ester series is not equivalent on a mass basis to the free phenolic API or to the sodium or hydrochloride salt; a molecular weight correction factor must be applied during formulation and dose calculation.

What Release Standards Apply to Injectable and Oral Solid Dosage Forms?

For injectable veterinary formulations, the low-endotoxin grade is released with a bacterial endotoxin test by the kinetic chromogenic method according to USP <85> or Ph. Eur. 2.6.14. The action limit is derived from the maximum intended daily dose and the target species dosing interval; a typical limit for a small-volume parenteral API is ≤0.5 EU/mg, but this must be justified in the veterinary product dossier because endotoxin sensitivity varies by species. Injectable lots are also tested for subvisible particulate matter after reconstitution or dilution; the finished product limits in USP <788> apply to the final container, not to the API alone. For oral solid dosage forms, the API is specified for particle size distribution by laser diffraction according to ISO 13320. The oral solid grade may have a D90 of ≤150 µm for direct compression and ≤250 µm for granulated or capsule powder fill, but the target must be selected from formulation process capability. Bulk and tapped density are measured according to USP <616>; a Hausner ratio below 1.35 is generally adequate for automatic die filling, while values above 1.35 indicate a need for roller compaction, slugging, or glidant addition. The following release matrix summarizes the grade selection tests.

Direct compression of the ester series in low-dose tablets requires geometric dilution with a directly compressible filler such as microcrystalline cellulose or spray-dried lactose. The ester series may exhibit poor flow because of fine particles generated during jet-milling; the flow defect is observed on high-speed rotary presses as weight variation beyond ±5% and occasional sticking to the lower punch. To reduce the sticking tendency, sodium stearyl fumarate at 0.5–1.0% is often preferred over magnesium stearate because the latter can prolong disintegration time at hydrophobic loadings above 1.0%. Tablet hardness is monitored with a Schleuniger-type apparatus, and friability is tested according to USP <1216>; disintegration testing is performed according to USP <701>, and dissolution testing follows USP <711> or the relevant veterinary product monograph. For capsules, the powder is filled after blending with a lubricant and, where needed, a dry granulation step using a roller compactor with roll pressure between 20 kN and 50 kN; ribbon density is monitored by near-infrared reflectance to maintain granule porosity. Aqueous wet granulation is acceptable only if the granulation end-point pH is maintained below 6.0 and drying temperature does not exceed 50 °C to prevent ester hydrolysis. The product is blended in a bin blender or V-blender; blending time is established by blend uniformity testing with samples taken at 10, 20, and 30 minutes. Acceptance criteria for blend uniformity follow USP <905> for tablets or capsules, with a relative standard deviation not more than 5.0% for the active peak area.

When the Ester Series Is Formulated as an Aqueous Injection or Oral Solution

Solution formulations require pH control because the ester linkage undergoes base-catalyzed hydrolysis. In pure water at 25 °C, the solubility of the longer-chain ester grades may be below 5 mg/mL, while the short-chain methyl ester may fall between 10 mg/mL and 20 mg/mL; published data for this specific configuration is limited and must be verified by equilibrium solubility studies under Ph. Eur. 5.11 or USP <1236>. Injectable solutions above 20 mg/mL typically require a co-solvent system of PEG 400 or propylene glycol at 10–40% v/v, with water for injection as the remaining vehicle. The pH is adjusted to 4.0–6.0 with citrate or acetate buffer; autoclaving at 121 °C for 15 minutes is not recommended unless the formulation shows less than 5% total degradation and no free phenol increase above the specification. Aseptic filtration through a 0.22 µm PVDF or PES filter is the preferred sterilisation route; filter compatibility should be assessed by bubble point and extractable profiling according to the filter manufacturer's technical file. Terminal sterilisation by gamma irradiation at 25 kGy is not recommended without validation because ester bond scission can occur. For oral solutions, a preservative system is required if the product is a multi-dose container; parabens are not automatically compatible because the product itself is a hydroxyphenyl ester, and analytical interference with preservative peaks must be resolved. Sodium metabisulfite at 0.1% may be added as an antioxidant, but sulfite adducts can form at low pH; nitrogen blanketing is recommended during filling. The solution should be stored in amber Type I glass or high-density polyethylene containers with low oxygen transmission. Container closure integrity testing should follow USP <1207> for parenteral products; stoppers should be butyl rubber with a fluoropolymer coating to reduce partitioning of the ester into plain rubber.

For feed premix and granulated oral powders, the ester series is dispersed onto a carrier such as calcium carbonate, lactose monohydrate, wheat semolina, or corn cob grit. The selected carrier is dried when equilibrium relative humidity exceeds 60%; free moisture above 1.0% can cause API agglomeration and electrostatic segregation during mixing. A concentrated pre-blend is prepared by geometric dilution at 1:10 or 1:20 with the carrier, then transferred to a ribbon mixer, paddle mixer, or double-cone blender. Mixing time is established by sampling the premix from the top, middle, and bottom zones; the API content should fall within ±10% of label claim for preliminary mixing, with final acceptance tightened to ±5% when the premix is a semi-finished intermediate. Horizontal ribbon mixers should be filled to approximately 70% of gross volume; fill levels above 80% reduce mixing efficiency and increase dead zones. Pneumatic conveying of the finished premix should be grounded to avoid electrostatic charges, and ionisation bars may be needed in dry environments below 30% RH. The granulated model of the ester series is preferred for premix because it has a higher bulk density and lower dusting potential than the micronized oral solid grade. Anti-dusting agents, such as vegetable oil at 0.5–1.0%, are added after the active carrier pre-blend is uniform. The premix is filled into multi-wall paper sacks or polyethylene-lined woven bags and stored below 30 °C and below 65% RH; caking is minimized by avoiding direct contact with concrete floors.

Chromatographic Impurity Profiles Against Free Phenolic APIs

The ester series is differentiated from the free phenolic API by the related-substances profile, not by the core pharmacophore. Esterification introduces residual carboxylic acid, residual alcohol or benzyl halide, free phenol, and possible dimeric transesterification products. The HPLC method uses a reversed-phase C18 column of dimensions 250 × 4.6 mm, 5 µm particle size, and a UV detector at 254 nm. A gradient mobile phase of phosphate buffer at pH 3.0 and acetonitrile is typical. The method must resolve free phenol from the ester peak with a resolution of not less than 1.5, and the tailing factor for the ester peak should be not more than 2.0. Free phenolic content in the ester series is controlled at ≤1.0% for oral non-sterile grades and ≤0.5% for sterile injectable grades, which is stricter than in many sodium or hydrochloride salt materials because the free phenol contributes to colour formation and oxidative instability in solution. Compared with the free phenolic API, the ester series shows lower hygroscopicity as measured by dynamic vapour sorption at 25 °C and 60% RH; however, the esterified material is more susceptible to alkaline hydrolysis. Compared with sodium or hydrochloride salt forms, the ester series avoids additional counterion burden, but it requires the formulator to calculate the active phenolic moiety per unit mass from the molecular weight ratio stated on the certificate of analysis. In solid oral formulations, the ester series is expected to show lower discolouration than the free phenol during accelerated storage at 40 °C/75% RH for 6 months; published data for this specific configuration is limited, so matrix-specific stability studies are required before filing. The veterinary grade API should not be confused with preservative-grade hydroxyphenyl esters such as alkyl parabens used as excipients; the API is released with active moiety content and impurity limits suitable for drug product manufacturing, while preservative grades are controlled for antimicrobial activity and may contain higher unspecified impurities.